Security key
29286M113
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)
CUSIP: 29286M113
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / *W EXP 10/31/202
- Total 13F shares
- 5,502,863
- Share change
- +806,840
- Total reported value
- $28,624,959
- Price per share
- $5.20
- Number of holders
- 16
- Value change
- +$9,669,204
- Number of buys
- 3
- Number of sells
- 13
Report period
Q1 2024
Institutions
16
Top holders
10
ENGNW full security history
Newer quarter: Q2 2024
Previous quarter: Q4 2023
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29286M113
Recent filing periods:
Top shareholders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vivo Capital, LLC |
13F
|
Company |
1%
|
678,705
|
$6,264,447 | — | 31 Dec 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.06%
|
37,845
|
$349,000 | — | 31 Dec 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.06%
|
37,447
|
$345,636 | — | 31 Dec 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.03%
|
20,057
|
$185,126 | — | 31 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,937
|
$17,879 | — | 31 Dec 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
8
|
$74 | — | 31 Dec 2023 | |
| Lumira Capital Investment Management Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,849,299
|
$38,492,990 | — | 20 Feb 2024 | |
| Forbion Growth Sponsor FEAC I B.V. |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
5,502,338
mixed-class rows
|
— | — | 31 Oct 2023 | |
| Forbion Capital Fund III Cooperatief U.A. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,894,735
|
— | — | 31 Oct 2023 | |
| BVF PARTNERS L P/IL |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
104,257
|
— | — | 31 Oct 2023 | |
| FCPM III SERVICES B.V. |
13F
|
Company |
—
mixed-class rows
|
12,556,099
mixed-class rows
|
$82,543,914 | — | 31 Dec 2023 | |
| BVF INC/IL |
13F
|
Company |
—
mixed-class rows
|
3,196,439
mixed-class rows
|
$21,580,664 | — | 31 Dec 2023 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
—
mixed-class rows
|
1,709,837
mixed-class rows
|
$11,800,650 | — | 31 Dec 2023 | |
| Omega Fund Management, LLC |
13F
|
Company |
—
mixed-class rows
|
1,606,252
mixed-class rows
|
$10,844,560 | — | 31 Dec 2023 | |
| Polar Asset Management Partners Inc. |
13F
|
Company |
—
mixed-class rows
|
297,665
mixed-class rows
|
$1,276,884 | — | 31 Dec 2023 | |
| Saba Capital Management, L.P. |
13F
|
Company |
—
class O/S missing
|
230,470
|
$270,802 | — | 31 Dec 2023 | |
| Calamos Advisors LLC |
13F
|
Company |
—
class O/S missing
|
250,000
|
$212,500 | — | 31 Dec 2023 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
—
class O/S missing
|
138,712
|
$117,905 | — | 31 Dec 2023 | |
| AQR Arbitrage LLC |
13F
|
Company |
—
class O/S missing
|
127,339
|
$108,238 | — | 31 Dec 2023 | |
| TENOR CAPITAL MANAGEMENT Co., L.P. |
13F
|
Company |
—
class O/S missing
|
116,666
|
$99,166 | — | 31 Dec 2023 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
—
class O/S missing
|
104,722
|
$89,014 | — | 31 Dec 2023 | |
| PERISCOPE CAPITAL INC. |
13F
|
Company |
—
class O/S missing
|
100,000
|
$85,000 | — | 31 Dec 2023 | |
| Atalaya Capital Management LP |
13F
|
Company |
—
class O/S missing
|
66,666
|
$56,666 | — | 31 Dec 2023 | |
| Shaolin Capital Management LLC |
13F
|
Company |
—
class O/S missing
|
50,000
|
$42,500 | — | 31 Dec 2023 | |
| Exos TFP Holdings LLC |
13F
|
Company |
—
class O/S missing
|
35,491
|
$30,167 | — | 31 Dec 2023 | |
| KIM, LLC |
13F
|
Company |
—
class O/S missing
|
33,333
|
$28,333 | — | 31 Dec 2023 | |
| WHITEBOX ADVISORS LLC |
13F
|
Company |
—
class O/S missing
|
33,333
|
$28,333 | — | 31 Dec 2023 | |
| ARISTEIA CAPITAL, L.L.C. |
13F
|
Company |
—
class O/S missing
|
24,045
|
$28,253 | — | 31 Dec 2023 | |
| CLEAR STREET LLC |
13F
|
Company |
—
class O/S missing
|
28,410
|
$24,149 | — | 31 Dec 2023 | |
| CSS LLC/IL |
13F
|
Company |
—
class O/S missing
|
27,000
|
$22,950 | — | 31 Dec 2023 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
—
class O/S missing
|
23,570
|
$20,035 | — | 31 Dec 2023 | |
| Sculptor Capital LP |
13F
|
Company |
—
class O/S missing
|
11,300
|
$13,278 | — | 31 Dec 2023 | |
| Walleye Capital LLC |
13F
|
Company |
—
class O/S missing
|
11,200
|
$9,520 | — | 31 Dec 2023 | |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
5,633
|
$4,788 | — | 31 Dec 2023 | |
| Jason David Hanson |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
512,826
|
— | — | 31 Oct 2023 | |
| Richard P. Bryce |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
153,000
|
— | — | 30 Nov 2023 | |
| James C. Sullivan |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
118,509
|
— | — | 31 Oct 2023 |
Institutional Holders of enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW) as of Q1 2024
As of 31 Mar 2024,
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,502,863 shares.
The largest 10 holders included
FCPM III SERVICES B.V., BVF INC/IL, Blue Owl Capital Holdings LP, Omega Fund Management, LLC, Saba Capital Management, L.P., Calamos Advisors LLC, D. E. Shaw & Co., Inc., Polar Asset Management Partners Inc., Atalaya Capital Management LP, and TENOR CAPITAL MANAGEMENT Co., L.P..
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
21
Q1 2024 holders
16
Holder diff
-5
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.